Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of September 2017. The registrant is a foreign private issuer based in Ness Ziona, Israel, focused on pharmaceutical development.
Key Financial Metrics
The filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Expected to be $10.0 million from the offering, including the full exercise of the overallotment option.
- Offering Price: $6.00 per American Depositary Share (ADS).
- Shares Issued: 1,500,000 ADSs initially, plus 166,667 ADSs via the overallotment option (total 1,666,667 ADSs).
- ADS Conversion: Each ADS represents 40 ordinary shares.
- Net Proceeds: The filing does not provide a clear value for net proceeds after deducting underwriting discounts and offering expenses.
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide clear values for these operational metrics.
Material Changes
The primary material change is the execution of an Underwriting Agreement on September 13, 2017, with Joseph Gunner & Co., LLC. This represents a significant increase in the company's capital base pending the closing of the transaction.
Outlook, Risks, and Management Commentary
- Closing Date: The offering is expected to close on September 18, 2017.
- Regulatory Basis: The offering is made pursuant to an effective shelf registration statement on Form F-3 (Registration No. 333-214439).
- Legal Contingencies: The transaction is subject to customary representations, warranties, covenants, and indemnification rights detailed in the Underwriting Agreement (Exhibit 1.1).
- Overallotment: The 45-day option to purchase additional shares has been exercised in full.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected September 18, 2017) and confirm receipt of funds.
- Review the final prospectus supplement to determine the exact underwriting discounts and commissions to calculate net proceeds.
- Confirm the total number of ADSs outstanding post-offering to assess dilution impact.
- Examine the Underwriting Agreement (Exhibit 1.1) for any specific lock-up periods or restrictive covenants.